3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Phase 2
1
Status
Completed
22
Terminated
9
Active not recruiting
4
Recruiting
3
Unknown
2
Withdrawn
1
Sponsor Class
INDUSTRY
2
NETWORK
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Plasma cell
1
Lymphoid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Chronic-Phase
1
Blast Crisis
1
Interventions
pembrolizumab
555
Specimen Handling
459
Carboplatin
446
Magnetic Resonance Spectroscopy
427
Cyclophosphamide
412
Cisplatin
404
Gemcitabine
314
Radiotherapy
313
Bevacizumab
310
Paclitaxel
300
Biopsy
260
Drug Therapy
252
Capecitabine
241
Oxaliplatin
240
fludarabine
236
Nivolumab
226
venetoclax
225
Injections
214
Docetaxel
203
Fluorouracil
201
Dexamethasone
186
Radiosurgery
172
Rituximab
161
Pemetrexed
157
durvalumab
144
Standard of Care
143
atezolizumab
139
toripalimab
137
tislelizumab
137
Leucovorin
137
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
bosutinib
×
Clear all
NCT04877522
2026-05-11
Asciminib Roll-over Study
Novartis
Phase 4
Recruiting
347 enrolled
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled
NCT06423911
2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3
Recruiting
285 enrolled